‘Frontier science’ investor KdT Ventures wraps up third fund at $80m

The fund's limited partners include institutional investment firms as well as technology and life science industry leaders.

  • Austin-based firm invests in data, engineering, biology and healthcare
  • The fund will focus on pre-seed and seed companies
  • Portfolio is said to have an enterprise value of more than $4bn

KdT Ventures, which describes itself as a “frontier science” investor, has closed its third fund at $80 million, a 60 percent increase from its sophomore fund.

The Austin-based firm did not disclose the names of investors, but Fund III limited partners include institutional investment firms as well as technology and life science industry leaders, it said in a statement.

Like prior funds, Fund III will focus on pre-seed and seed companies.

KdT raised $15 million for its debut fund in 2018 and $50 million for Fund II last year, according to PitchBook.

In conjunction with the fundraising, KdT promoted Dr. Phil Grayeski and Rima Chakrabarti to partners. Additionally, Ketan Yerneni was promoted from associate to principal.

“Phil and Rima consistently demonstrate the core values of compassion and grit that are central to KdT as a firm,” founder and managing partner Cain McClary said in the statement. “We look forward to their continued influence as the portfolio and firm grow.”

KdT Ventures focuses on the sectors of data, engineering, biology sector and healthcare technology. Its current portfolio has an enterprise value of more than $4 billion, the firm said.